Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EpiTAF: PK of Tenofovir Alafenamide with Rifampicin in TB/HIV
NCT04424264Phase 1Completed
- Start
- Dec 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tenofovir alafenamide in human immunodeficiency virus type 1 infection (HIV-1). Primary endpoint: Intracellular Tenofovir-diphosphate concentrations at 56 days. Started Dec 2019; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04424264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04424264.